Related Experiment Video
Updated: Aug 1, 2025
07:24
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
6.5K
Long non-coding RNA MAFG-AS1: A promising therapeutic target for human cancers
Zhiyu Huang1, Maoqing Zhang1, Jiayue Li1
1School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Summary
Long non-coding RNA MAFG-antisense 1 (MAFG-AS1) is overexpressed in many cancers, promoting proliferation and metastasis. This review highlights MAFG-AS1 as a potential prognostic marker and therapeutic target for cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Long non-coding RNAs (lncRNAs) play critical roles in cancer development.
- MAFG-antisense 1 (AS1) (MAFG-AS1) is identified as a novel oncogenic lncRNA.
- MAFG-AS1 overexpression is observed in various human cancers, including breast, bladder, liver, gastric, and lung.
Purpose of the Study:
- To review the biological properties and molecular mechanisms of MAFG-AS1 in human cancers.
- To summarize the clinicopathological significance of MAFG-AS1.
- To evaluate MAFG-AS1 as a prognostic biomarker and therapeutic target.
Main Methods:
- Literature review of existing studies on MAFG-AS1.
- Analysis of MAFG-AS1's role in regulating microRNAs and cell signaling pathways.
- Correlation analysis of MAFG-AS1 expression with clinicopathological features.
Main Results:
- MAFG-AS1 regulates proliferation, metastasis, and epithelial-mesenchymal transition (EMT).
- Overexpression of MAFG-AS1 correlates with advanced histological grade, TNM stage, invasion depth, poor overall survival (OS), and lymph node metastasis (LNM).
- MAFG-AS1 influences various cancer cell signaling pathways.
Conclusions:
- MAFG-AS1 is a significant oncogenic lncRNA in human cancers.
- MAFG-AS1 serves as a promising prognostic biomarker.
- MAFG-AS1 represents a potential therapeutic target for cancer treatment.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
8.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K
01:22MicroRNAs
3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
02:15Experimental RNAi
6.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
03:18Non-LTR Retrotransposons
11.6K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.6K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K